Skip to contentpdufa.bio

IPH4502 (Nectin-4 exatecan ADC)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

IPH4502 (Nectin-4 exatecan ADC) is an Innate Pharma SA program in solid tumors.

IPHA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Solid tumors. Sponsor: Innate Pharma SA (IPHA). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Nov 18, 2026IPHA

Questions

When is IPH4502 (Nectin-4 exatecan ADC)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for IPH4502 (Nectin-4 exatecan ADC); no FDA decisions are on record below.

What happened at IPH4502 (Nectin-4 exatecan ADC)'s most recent FDA decision?

No FDA decision for IPH4502 (Nectin-4 exatecan ADC) is in our archive yet.

What is IPH4502 (Nectin-4 exatecan ADC) used for?

In our records IPH4502 (Nectin-4 exatecan ADC) is under review or in development for Solid tumors.

Who makes IPH4502 (Nectin-4 exatecan ADC)?

Innate Pharma SA (IPHA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.